| Issue Date | Title | Author(s) |
| 2021-07-01 | Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19 | Jeyaraman, M; Muthu, S; Bapat, A; Jain, R; ES, S; Gulati, A; Channaiah Anudeep, T; Dilip, SJ; Jha, NK; Kumar, D; Kesari, KK; Ojha, S; Dholpuria, S; Gupta, G; Dureja, H; Chellappan, DK; Singh, SK; Dua, K; Jha, SK |
| 2021-09 | Inhaled nano-based therapeutics for inflammatory lung diseases: Recent advances and future prospects | Gulati, N; Chellappan, DK; MacLoughlin, R; Dua, K; Dureja, H |
| 2021-03-09 | Calcium sensing receptor hyperactivation through viral envelop protein E of SARS CoV2: A novel target for cardio‐renal damage in COVID‐19 infection | Singh, Y; Ali, H; Alharbi, KS; Almalki, WH; Kazmi, I; Al‐Abbasi, FA; Anand, K; Dureja, H; Singh, SK; Thangavelu, L; Chellappan, DK; Dua, K; Gupta, G |
| 2021-12 | Microfluidic chips: recent advances, critical strategies in design, applications and future perspectives | Pattanayak, P; Singh, SK; Gulati, M; Vishwas, S; Kapoor, B; Chellappan, DK; Anand, K; Gupta, G; Jha, NK; Gupta, PK; Prasher, P; Dua, K; Dureja, H; Kumar, D; Kumar, V |
| 2021-10-15 | Protein and peptide delivery to lungs by using advanced targeted drug delivery. | Chellappan, DK; Prasher, P; Saravanan, V; Vern Yee, VS; Wen Chi, WC; Wong, JW; Wong, JK; Wong, JT; Wan, W; Chellian, J; Molugulu, N; Prabu, SL; Ibrahim, R; Darmarajan, T; Candasamy, M; Singh, PK; Mishra, V; Khurana, N; Shastri, MD; Satija, S; Zacconi, FC; Chakraborty, A; Mehta, M; Gupta, PK; Dureja, H; Gulati, M; Singh, SK; Gupta, G; Jha, NK; George Oliver, BG; Dua, K |
| 2021-01 | Induction of Caspase-Mediated Apoptosis in HepG2 Liver Carcinoma Cells Using Mutagen-Antioxidant Conjugated Self-Assembled Novel Carbazole Nanoparticles and In Silico Modeling Studies. | Anand, K; Abdul, NS; Ghazi, T; Ramesh, M; Gupta, G; Tambuwala, MM; Dureja, H; Singh, SK; Chellappan, DK; Dua, K; Pandi, B; Saravanan, M; Chuturgoon, AA |
| 2021-02 | Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities. | Lee, L-Y; Hew, GSY; Meenu,; Shukla, SD; Satija, S; Khurana, N; Anand, K; Dureja, H; Singh, SK; Mishra, V; Singh, PK; Gulati, M; Prasher, P; Aljabali, AAA; Tambuwala, MM; Thangavelu, L; Panneerselvam, J; Gupta, G; Zacconi, FC; Shastri, M; Jha, NK; Xenaki, D; MacLoughlin, R; Oliver, BG; Chellappan, DK; Dua, K |
| 2022-01-01 | Advanced drug delivery systems targeting metabolic disorders: erythropoietic protoporphyria | Verma, N; Thapa, K; Kanojia, N; Dureja, H; Dua, K |
| 2022-01-01 | Advanced drug delivery system in the treatment of hyperglycemia and hypoglycemia | Arora, V; Kabra, A; Sharma, RB; Dureja, H; Dua, K |
| 2023-02 | Chitosan-based nano drug delivery system for lung cancer | Kazmi, I; Shaikh, MAJ; Afzal, O; Alfawaz Altamimi, AS; Almalki, WH; Alzarea, SI; Al-Abbasi, FA; Pandey, M; Dureja, H; Singh, SK; Dua, K; Gupta, G |
